Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry

MLA

Leslie R. Harrold, et al. “Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.” Rheumatology and Therapy, vol. 6, no. 2, Mar. 2019, pp. 217–30. EBSCOhost, https://doi.org/10.1007/s40744-019-0149-3.

APA

Leslie R. Harrold, Heather J. Litman, Sean E. Connolly, Evo Alemao, Sheila Kelly, Sabrina Rebello, Winnie Hua, & Joel M. Kremer. (2019). Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. Rheumatology and Therapy, 6(2), 217–230. https://doi.org/10.1007/s40744-019-0149-3

Chicago

Leslie R. Harrold, Heather J. Litman, Sean E. Connolly, Evo Alemao, Sheila Kelly, Sabrina Rebello, Winnie Hua, and Joel M. Kremer. 2019. “Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.” Rheumatology and Therapy 6 (2): 217–30. doi:10.1007/s40744-019-0149-3.